IN LEQVIO PHASE III CLINICAL
TRIALS OVER 18 MONTHS
Most common adverse reactions in
≥3% of patients treated
with
LEQVIO and more frequently than
placebo1

ªIncludes related terms such as injection site pain,
erythema, and rash.
2.5% of patients discontinued LEQVIO vs 1.9% with placebo1
Injection site reactions were the most common causes for treatment discontinuation (0.2% of patients taking LEQVIO vs 0% taking placebo)1
-
All were localized, predominantly mild, or occasionally moderate4
-
LEQVIO has no warnings and precautions or contraindications included in the prescribing information1
-
No clinically significant drug-drug interactions are expected with LEQVIO1
The safety profile of LEQVIO
was
consistent across all
subgroups,
including
elderly,
hepatic, and renally impaired
patient populations1*
*LEQVIO was not studied in patients with end-stage renal disease or severe hepatic impairment.
IN ORION-3 (n=374),
4-YEAR SAFETY WAS
CONSISTENT WITH PHASE III CLINICAL TRIALS1,15
• NO NEW SAFETY SIGNALS15
View Study Design & LimitationsThe safety profile of LEQVIO was consistent across all subgroups, including elderly, hepatic, and renally impaired patient populations1*
*LEQVIO was not studied in patients with end-stage renal disease or severe hepatic impairment.
IN ORION-3 (n=374), 4-YEAR
SAFETY WAS CONSISTENT
WITH PHASE III CLINICAL
TRIALS1,15
• NO NEW SAFETY SIGNALS15
View Study Design & Limitations
Take a moment to refresh your
understanding of the LEQVIO safety profile
THERE'S MORE TO
KNOW ABOUT LEQVIO
Effective and sustained
LDL-C reduction is
possible for your patients1†

†Greater LDL-C reducation was maintained
during each 6-month dosing interval vs
placebo as a complement to a maximally
tolerated statin.